Kiniksa Pharmaceuticals Ltd (KNSA) is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates target immunological and inflammatory diseases, such as prurigo nodularis, autoinflammatory disease, and severe asthma. Kiniksa's pipeline includes several drug candidates in various stages of development, including rilonacept, mavrilimumab, vixarelimab, and KPL-404. Rilonacept is a recombinant fusion protein that has been approved by the US FDA for the treatment of cryopyrin-associated periodic syndromes (CAPS). Mavrilimumab is a fully human monoclonal antibody that targets the IL-6 receptor, which is being developed for the treatment of giant cell arteritis (GCA) and COVID-19. Vixarelimab is a monoclonal antibody that is being developed for the treatment of prurigo nodularis, a chronic skin disease. KPL-404 is a monoclonal antibody that targets CD40L, which is being developed for the treatment of autoimmune and inflammatory diseases. Kiniksa Pharmaceuticals was founded in 2015 and is headquartered in Lexington, Massachusetts.
Kiniksa Pharmaceuticals Ltd (KNSA) is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates target immunological and inflammatory diseases, such as prurigo nodularis, autoinflammatory disease, and severe asthma. Kiniksa's pipeline includes several drug candidates in various stages of development, including rilonacept, mavrilimumab, vixarelimab, and KPL-404. Rilonacept is a recombinant fusion protein that has been approved by the US FDA for the treatment of cryopyrin-associated periodic syndromes (CAPS). Mavrilimumab is a fully human monoclonal antibody that targets the IL-6 receptor, which is being developed for the treatment of giant cell arteritis (GCA) and COVID-19. Vixarelimab is a monoclonal antibody that is being developed for the treatment of prurigo nodularis, a chronic skin disease. KPL-404 is a monoclonal antibody that targets CD40L, which is being developed for the treatment of autoimmune and inflammatory diseases. Kiniksa Pharmaceuticals was founded in 2015 and is headquartered in Lexington, Massachusetts.